Cryoport's Q1 2026 Earnings: Solid Growth & Future Approvals

Cryoports Q1 2026 earnings show robust growth, with revenue up 16% to $47.8M, driven by increased commercial cell & gene therapy support (26% to $9.1M) and clinical trials (18% to $12.9M). They now support 766 global clinical trials, up 55 from last year, with 91 in late-stage Phase III. Life Sciences Services grew 18%, biostorage 21%, and Products 15%. Despite macro uncertainty, Cryoport remains bullish, expecting high single-digit growth in products and positive adjusted EBITDA in the second half. Key achievements include launching the MVE Fusion 800 series and integrating AI for operational efficiency. With raised full-year guidance to $192-196M, Cryoport solidifies its position as the cell and gene supply chain leader. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/dfd2b2d6e8ad2367